SCAILYTE

Scailyte is a pioneer in leveraging artificial intelligence for deep insights from high-dimensional cellular data, with foundational expertise in single-cell analysis. Born as an ETH Zürich spin-off in 2017, we are now a clinical-stage precision medicine company dedicated to developing our own pipeline of breakthrough diagnostic and companion diagnostic (CDx) solutions. Our mission is to transform healthcare in complex diseases like cancer and autoimmune disorders by ensuring the right patient receives the right treatment. We achieve this by applying our best-in-class, explainable AI platform, ScaiVision, to unique multimodal datasets (including single-cell, spatial, immune profiling, and other omics), often enriched through our clinical network. Our discoveries directly fuel our product development, and all our work is underpinned by high industry standards and driven by a great, diverse, and complementary team working in tight synergy to translate cutting-edge science into clinical..

Also known as: Scailyte AG, Scailyte AG and Bloom SA

Primary location: Basel Switzerland